Sign in →

Test ID NGSFX Reanalysis of Acute Myeloid Leukemia 4- or 11- Gene Panels, Additional Genes


Specimen Required


No additional specimen is required. This is a bioinformatics review of additional gene regions not analyzed in the previously ordered NGAMT / Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing or NGAML / Acute Myeloid Leukemia, 11-Gene Panel. Call 800-533-1710 for assistance with ordering.


Useful For

Comprehensive reanalysis of a larger set of genes/gene regions when a more targeted gene panel was previously performed in this laboratory

 

Evaluation of known or suspected hematologic neoplasms, specifically of myeloid origin (eg, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm, unexplained cytopenias) at the time of diagnosis or possibly disease relapse, to help determine diagnostic classification and provide prognostic or therapeutic information for helping guide clinical management

 

Determine the presence of new clinically important gene mutation changes at relapse

Genetics Test Information

This test includes next-generation sequencing to evaluate the following 47 genes and select intronic regions: ANKRD26, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS, MPL, NF1, NPM1, NRAS, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SH2B3, SF3B1, SMC3, SRSF2, STAG2, STAT3, TERT, TET2, TP53, U2AF1, UBA1, WT1, and ZRSR2.

Testing Algorithm

Only orderable as a reflex. Reflex testing is available upon request within 6 months of original NGAMT / Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next Generation Sequencing, Varies or NGAML / Acute Myeloid Leukemia, 11-Gene Panel, Varies sample submission.

 

This is a bioinformatics and variant review only for the added gene regions.

 

For a list of genes and exons targeted by this test see Targeted Genes Interrogated by Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing.

Method Name

Only orderable as a reflex. For more information, see:

-NGAMT / Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) Next-Generation Sequencing, Varies

-NGAML / Acute Myeloid Leukemia, 11-Gene Panel, Varies.

 

Next-Generation Sequencing (NGS)

Reporting Name

Reanalysis, AML 4 or 11 Gene Panel

Specimen Type

Varies

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies 14 days

Reference Values

Only orderable as a reflex. For more information, see:

-NGAMT / Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing, Varies

-NGAML / Acute Myeloid Leukemia, 11-Gene Panel, Varies.

Day(s) Performed

Monday through Friday

Report Available

16 to 21 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81450

LOINC Code Information

Test ID Test Order Name Order LOINC Value
NGSFX Reanalysis, AML 4 or 11 Gene Panel In Process

 

Result ID Test Result Name Result LOINC Value
MP043 Specimen Type 31208-2
NFXID Diagnosis/Indication 29308-4
601695 NGSFX Result No LOINC Needed
601687 Pathogenic Mutations Detected 82939-0
601686 Interpretation 69047-9
601688 Clinical Trials 82786-5
601689 Variants of Unknown Significance 93367-1
601690 Additional Notes 48767-8
601691 Method Summary 85069-3
601692 Disclaimer 62364-5
601693 NGSFX Panel Gene List 36908-2
601694 Reviewed By: 18771-6

NY State Approved

Yes